Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrated Diagnostics Holdings has a Cash Ratio of 0.00. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Integrated Diagnostics Holdings's Cash Ratio or its related term are showing as below:
LSE:IDHC'
s Cash Ratio Range Over the Past 10 Years
Min: 0.36 Med: 0.81 Max: 1.62
Current: 0.79
During the past 13 years, Integrated Diagnostics Holdings's highest Cash Ratio was 1.62. The lowest was 0.36. And the median was 0.81.
LSE:IDHC's Cash Ratio is ranked worse than 55.07% of 207
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.99
vs LSE:IDHC: 0.79
Integrated Diagnostics Holdings (LSE:IDHC) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Integrated Diagnostics Holdings Cash Ratio Related Terms
Integrated Diagnostics Holdings Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Diagnostics Holdings Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Integrated Diagnostics Holdings's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Diagnostics Holdings (LSE:IDHC) has a Cash Ratio of 0.00 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Integrated Diagnostics Holdings and its competitors. Over the past decade, Integrated Diagnostics Holdings' Cash Ratio has ranged from 0.36 to 1.62. According to the industry distribution chart, Integrated Diagnostics Holdings ranks #114 out of 207 companies in the Medical Diagnostics & Research industry, placing it in the top 55.1%.
Is Integrated Diagnostics Holdings' Cash Ratio too high?
Integrated Diagnostics Holdings' current Cash Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 1.62. Based on the distribution chart, Integrated Diagnostics Holdings ranks #114 out of 207 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Integrated Diagnostics Holdings has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' Cash Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integrated Diagnostics Holdings ranks #114 out of 207 companies for Cash Ratio. This places Integrated Diagnostics Holdings in the lower half of its industry. The industry median Cash Ratio is 0.99. Historically, Integrated Diagnostics Holdings' own Cash Ratio has ranged from 0.36 to 1.62 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 0.99, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Integrated Diagnostics Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 0.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Diagnostics Holdings's current Cash Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Fairly Valued. The stock's GF Value™ is $0.60, compared to a current price of $0.61 — trading 1.3% above its estimated fair value. The current Cash Ratio is 0.00. Integrated Diagnostics Holdings' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current Cash Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be overvalued.
The current stock price of $0.61 is trading 1.3% above its estimated GF Value™ of $0.60.
GuruFocus considers Integrated Diagnostics Holdings to be Fairly Valued.
Key valuation signals for LSE:IDHC:
Cash Ratio: 0.00
GF Value™: $0.60 vs. price of $0.61 (1.3% above fair value)
No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
58GF Score
Get the complete analysis for LSE:IDHC
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IDHC has been successfully added to your 
